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Background: The platelet glycoprotein IIb/IIIa inhibitor tirofiban hydrochloride
improves outcome in patients with acute coronary syndrome. Nevertheless, a con-
siderable number of patients require emergency or urgent coronary artery bypass
grafting and may be at increased risk of postoperative bleeding after treatment with
this molecule. The aim of this study is to evaluate the incidence of bleeding com-
plications among patients undergoing bypass grafting after treatment with tirofiban.
Methods: We investigated the influence of the molecule on postoperative bleeding
after cardiac surgery, comparing 2 groups of patients undergoing emergency or
urgent coronary artery bypass grafting: group A (n = 20) received tirofiban, and
group B (n = 68) received conventional therapy with intravenous heparin up until
the operation. A total of 88 patients underwent coronary artery bypass surgery
within 2 hours of ceasing the hemodynamic study. Clinical outcome, chest tube out-
puts, bleeding complications, transfusion requirements, platelet and hemoglobin
counts, and clinical complications were examined.
Results: Bleeding differences were noted between the 2 groups at 8, 16, and 24
hours postoperatively. The incidence of blood, platelet, and fresh frozen plasma
transfusions was higher in the control group. Postoperative thrombocytopenia was
preserved in group A (199.5 ± 70.4 vs 150.6 ± 33.4 103/mL, P < .01). No signifi-
cant differences were noted between the 2 groups in the incidence of perioperative
myocardial infarction, but significant differences were noted in enzyme levels,
length of stay in the intensive care unit, and length of stay in the hospital. No deaths
were observed. Hospital morbidity was increased in group B because of factors that
were not apparently linked with tirofiban infusion.
Conclusions: Patients may safely undergo coronary artery bypass surgery after
treatment with tirofiban hydrochloride. This molecule, administered in the immedi-
ate preoperative period, has no adverse clinical effects and does not seem to nega-
tively influence the incidence of perioperative myocardial infarction. Although
extracorporeal circulation can modify platelet numbers and function, our ongoing
data could show significant reduction in the loss of platelets induced by cardiopul-
monary bypass, minor postoperative bleeding, and a minor transfusion requirement
in general.
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Tirofiban hydrochloride (Aggrastat; Merck &Co, Inc, West Point, Pa) is a reversible, non-peptide inhibitor of the platelet glycoproteinIIb/IIIa receptor, the major platelet surfacereceptor involved in platelet aggregation. Incombination with heparin and aspirin, this
molecule is indicated for the treatment of acute coronary
syndrome because in this clinical setting, platelet-mediated
coronary thrombosis is the primary pathophysiologic mech-
anism. Platelet aggregation leads to thrombotic occlusion of
coronary arteries through cross-linking of glycoprotein
IIb/IIIa receptors on adjacent platelets by means of adhesive
plasma proteins, mostly fibrinogen.
Clinical studies (PRISM-PLUS, PRISM, and RESTORE)1,2
have confirmed the efficacy and safety of this kind of
antithrombotic therapy in patients with acute coronary syn-
drome (irrespective of the presence of percutaneous trans-
luminal coronary angioplasty). The impact of tirofiban and
the other glycoprotein IIb/IIIa inhibitors (abciximab and
eptifibatide) for the treatment of patients with acute coro-
nary syndrome modified the clinical outcome of these
patients,3 and therefore the horizon of the cardiac surgeon,
because even if drug therapy is well tolerated, a significant
number of patients need cardiac surgery after this treatment
and may be at increased risk of bleeding complications,
especially when emergency or urgent cardiac surgery is
necessary.4,5 The role of tirofiban in patients with cardiac
disease is not completely clear. It has been suggested that
glycoprotein IIb/IIIa inhibitors with a short half-life, like
tirofiban, have an improved safety profile and may produce
platelet anesthesia during cardiopulmonary bypass (CPB)
in experimental studies,6 preserving platelet numbers and
function. The aim of this study was to assess the clinical
events and potential bleeding complications in a cohort of
patients who had undergone emergency or urgent cardiac
surgery after treatment with tirofiban hydrochloride.
Patients and Methods
Patients 
From January 1999 to December 2000, a total of 764 coronary
artery bypass grafting operations were done. From this group of
patients, 88 underwent urgent or emergency treatment after acute
coronary syndrome. Emergency treatment was carried out when
the clinical status included shock, with or without circulatory sup-
port; pulmonary edema requiring intubation; acute evolving
myocardial infarction within 24 hours before the operation; and
ongoing ischemia, including angina at rest, despite maximal med-
ical therapy. Urgent treatment was applied in cases of unstable
angina with intravenous nitroglycerin or rest angina with or with-
out an intra-aortic balloon pump and in cases of bad coronary
anatomy, sudden chest pain, congestive heart failure, and acute
myocardial infarction. Patients were classified into 1 of 2 groups:
group A (tirofiban group, n = 20) received tirofiban treatment plus
aspirin, and group B (control group, n = 68) received treatment
with heparin plus aspirin. Group A comprised 14 male and 6
female patients and group B, 47 male and 21 female patients.
Mean age was 60.9 ± 8.7 years in group A and 63.2 ± 9.1 years in
group B. Left main stem disease was equally present in both
groups. Preoperative ejection fraction of the left ventricle was sim-
ilar. Five (25%) group A patients and 20 (29%) group B patients
required a significant dosage of a positive inotropic drug (defined
as intravenous dopamine infusion over 5 µg · kg–1 · min–1).
Patients were classified according to the Higgins clinical severity
score.7 Patient demographics, preoperative risk factors, and surgi-
cal times are summarized in Table 1.
Blood samples were obtained before and after the operation for
the measurement of hemoglobin levels, platelet counts, prothrom-
bin time, activated partial thromboplastin time, myocardial
enzymes, and activated clotting time (ACT). Blood samples were
taken before the operation (T1), after intensive care unit (ICU)
admission (T2), and before hospital discharge (T3). Mediastinal
chest tube output was collected in the ICU during the day of oper-
ation at the following time points: 8, 16, and 24 hours.
All group A patients with acute coronary syndrome (unstable
angina or non–Q-wave myocardial infarction) underwent treat-
ment with intravenous aspirin (bolus of 325 mg) and intravenous
heparin (bolus of 5000 IU followed by an infusion of 1000 IU/h
titrated to maintain an activated partial thromboplastin time of
approximately 2 times the control dose). Tirofiban was given as a
bolus dose at a dosage of 0.4 µg · kg–1 · min–1. Maintenance was
achieved by giving 0.10 µg · kg–1 · min–1. The infusion of tirofiban
must be given for a maximum of 72 hours. Patients with renal fail-
ure (creatinine level >2.0 mg/dL) were appointed to receive a half-
dose bolus and maintenance. Group B patients received only
aspirin plus heparin, as above. Tirofiban and heparin discontinua-
tion was only accomplished at skin incision.
Operative Technique
Patients were operated on through a median sternotomy.
Extracorporeal circulation with a roller pump and a hollow-fiber
oxygenator (Capiox SX18; Terumo Corporation, Tokyo, Japan)
primed with 1800 mL (± 200 mL) of buffered crystalloid solution
was instituted. Heparin (300 IU/kg) was given before cannulation
to achieve an ACT of greater than 400 seconds before CPB was
carried out. During CPB, the hematocrit level was maintained
between 20% and 25%. Myocardial protection was obtained
according to the protocol of the University of California at Los
Angeles Medical Center,8 with cold blood cardioplegic solution
delivered antegradely and retrogradely from the coronary sinus.
Before crossclamp release, modified cardioplegic reperfusion was
performed.9 The patients were weaned off CPB when rectal tem-
perature reached 34°C. After discontinuation of CPB, heparin was
reversed with protamine sulfate by use of a heparin-ACT dose-
response curve. Patients were weaned off mechanical ventilation
as soon as they were awake and breathing above the ventilator set
rate and when the following criteria were met: patient awake and
obeying commands; stable and adequate hemodynamics; no sig-
nificant arrhythmia; core temperature of greater than 36°C; chest
tube drainage of less than 100 mL/h for 2 consecutive hours;
diuresis of greater than 1 mL · kg–1 · h–1; pH of greater than 7.35;
PaCO2 of less than 50 mm Hg; PaO2 of greater than 70 mm Hg; and
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oxygen saturation as measured by pulse oximetry of 92% or
greater with the patient breathing less than 50% oxygen.
Statistical Analysis
Statistical analysis was performed with SPSS for Windows, ver-
sion 8.0 software (SPSS Inc, Chicago, Ill). Analysis of variance for
repeated measures and the Student t test were applied to continu-
ous variables. The χ2 test or, when appropriate, the Fisher exact
test was applied to categoric variables. The Mann-Whitney rank
sum test and Mann-Whitney U test were also applied for categoric
variables or when data did not follow a normal distribution. The
data are presented as means ± SD.
Results
In the immediate postoperative time (T2), we observed a
significant reduction in hemoglobin levels in both groups
compared with that of the preoperative time (T1): group A,
13.1 ± 0.9 vs 11.1 ± 1.2 g/dL (T1 vs T2, P < .01); group B,
13.5 ± 0.8 vs 10.3 ± 1.1 g/dL (T1 vs T2, P < .01). Before
hospital discharge (T3), hemoglobin values remained con-
stant in both groups. There was a significant difference in
hemoglobin levels between the tirofiban and control groups
at T2 (group A: 11.1 ± 1.2 g/dL vs group B: 10.3 ± 1.1 g/dL,
P < .01) and T3 (group A: 10.9 ± 1 g/dL vs group B: 10.1 ±
1.1 g/dL, P < .01; Figure 1).
Platelet values were similar in both groups at T1 (229 ±
31.2 vs 227.8 ± 29.7 103/mL, group A vs group B, P = .87)
but significantly different at T2 (199.5 ± 70.4 vs 150.6 ±
33.4 103/mL, group A vs group B, P < .01). We did not
observe a significant decrease in platelet numbers in the
tirofiban group between T1 and T2, whereas a significant
reduction was seen between T1 and T2 in group B (227.8 ±
27.9 vs 150.6 ± 33.4 103/mL, T1 vs T2, P < .01).
At T3, the platelet count revealed comparable values
between the 2 groups, and there was a significant increase
in platelet number with respect to T2 (199.5 ± 70.4 vs 288.8
± 115.2 103/mL, group A, T2 vs T3, P < .01; 150.6 ± 33.4
vs 281.3 ± 147.6 103/mL, group B, T2 vs T3, P < .01;
Figure 2).
Two (10%) patients in the tirofiban group and 28 (41%)
patients in the control group received a transfusion (P =
.02). There was a significant difference between the number
of units transfused in the control group, not only in red
blood cells but also in plasma and platelets (Table 2). There
was a significant difference in bleeding between the 2
TABLE 1. Patient demographics, preoperative risk factors,
and surgical time
Tirofiban group Control group
Value (n = 20) (n = 68) P value
Age (y) 60.9 ± 8.7 63.2 ± 9.1 .31
Age (min/max) 45/74 47/82 —
Male sex (%) 70 69 .84
Weight (kg) 77.8 ± 17.2 72.7 ± 12.7 .23
BSA (m2) 1.7 ± 0.6 1.8 ± 0.2 .47
EF (%) 55.4 ± 4.5 56.8 ± 5.1 .24
Left main stem (%) 50 51 .89
ASA (%) 83 76 .87
Higgins score 6.9 ± 1.4 7.4 ± 1.6 .18
Surgery time (min) 230.8 ± 51.4 239.8 ± 46.7 .48
Vessels bypassed (n) 1.3 ± 0.8 1.4 ± 0.7 .63
ITA (n) 1.2 ± 0.7 0.7 ± 0.4 .01
CPB time (min) 90.4 ± 32.8 104.2 ± 31.5 .10
Aortic crossclamp time (min) 68.2 ± 27.9 71.1 ± 21.1 .67
Values are expressed as means ± SD where shown. BSA, Body surface
area; EF, ejection fraction; ASA, acetylsalicilate acid; ITA, internal tho-
racic artery grafts.
Figure 1. Changes in hemoglobin (Hb) levels at different time
points. Hemoglobin levels dropped significantly in both groups at
T2. The difference in hemoglobin levels between the tirofiban and
control groups is statistically significant at T2 and T3. *P < .05,
tirofiban versus control. §P < .001, tirofiban and control (T1 vs T2).
Figure 2. Change in platelet count. A significant reduction is seen
between groups at T2. There is a significant reduction in platelet
count in the control group between T1 and T2. At T3, an increase
in the control group could be related to platelet transfusions. *P <
.05, tirofiban versus control. §P = .01, control (T1 vs T2). §§P < .05,
tirofiban and control (T2 vs T3).
1184 The Journal of Thoracic and Cardiovascular Surgery • December 2001
Cardiopulmonary Support and Physiology Bizzarri et al
ED
ITO
RIA
L
CH
D
G
TS
A
CD
ET
CSP
TX
groups at each observation time point after 8 hours (group
A: 127.5 ± 71.6 mL vs group B: 300.3 ± 226.3 mL, P <
.01), 16 hours (group A: 277.5 ± 119.7 mL vs group B:
440.2 ± 390.5 mL, P < .01), and 24 hours (group A: 354.5
± 139.6 mL vs group B: 544.5 ± 488.7 mL, P < .01; Figure
3). No myocardial infarctions (diagnosed when creatine
kinase MB increased by 5 to 10 times the upper normal
limit) occurred postoperatively in group A, but 2 were
observed in group B. Ejection fractions were also preserved
(ejection fraction = 0.554 in group A vs 0.572 in group B).
Significant differences were found between the 2 groups
in mechanical ventilation time and length of stay in the ICU
and in the hospital; however, the incidence of complications
was higher in group B, in which 20 (29%) patients had com-
plications (Table 3).
Discussion
Bleeding complications are a constant problem after cardiac
surgery, with 4% of patients requiring reentry into the oper-
ating theater after the first 24 hours after the operation.
Nonsurgical bleeding is responsible for 50% to 60% of this
reopening.10 Bleeding complications are related to the use
of heparin, the onset of fibrinolysis platelet dysfunction,
and a combination of these factors. Platelets are partially
activated by heparin and are diluted, destroyed, and modi-
fied during CPB because of the adhesion to circuit surfaces,
aggregation, and activation. Therefore, after CPB, a defi-
ciency in platelet number and function prolongs bleeding
times and contributes to postoperative bleeding.
Platelet-mediated coronary thrombosis is the primary
pathophysiologic mechanism of acute coronary syndrome
and is the main reason for the requirement for surgical inter-
vention.11 The final common pathway of platelet aggrega-
tion that leads to thrombotic occlusion of coronary arteries
involves the cross-linking of receptor glycoprotein IIb/IIIa
Figure 3. Chest tube drainage. Note the significant difference in
postoperative bleeding between the 2 groups after 8, 16, and 24
hours. *P < .01.
TABLE 2. Laboratory parameters before and after surgical
intervention, incidence of bleeding, chest tube output, trans-
fusion requirements, and hospital and ICU length of stay
Tirofiban group Control group
(n = 20) (n = 68) P value
Preoperative ACT (s) 107.2 ± 16.3 104.8 ± 10.6 .54
Postoperative ACT (s) 108.1 ± 18.1 106.7 ± 11.2 .74
Preoperative PT (%) 86.3 ± 8.1 86.2 ± 8.4 .96
Postoperative PT (%) 77.8 ± 15.4 78.2 ± 11.7 .91
Preoperative APTT (s) 72.4 ± 29.4 64.8 ± 32.5 .32
Postoperative APTT (s) 34.2 ± 10.7 36.8 ± 10.6 .34
Preoperative total CK (IU/L) 149.7 ± 232 134.5 ± 53.2 .77
Preoperative MB (IU/L) 6.17 ± 5.4 6.92 ± 7.8 .60
Preoperative MB (%) 6.3 ± 2.7 5.9 ± 2.6 .60
Postoperative total CK (IU/L) 316.5 ± 137 490 ± 297 .00
Postoperative MB (IU/L) 25.3 ± 20.3 38.1 ± 23.6 .03
Postoperative MB (%) 7.2 ± 4.4 9.6 ± 3.1 .03
CTO, 8 h (mL) 127.5 ± 71.6 300.3 ± 226.3 .00
CTO, 16 h (mL) 277.5 ± 119.7 448.2 ± 390.5 .00
CTO, 24 h (mL) 354.5 ± 139.6 544.5 ± 488.7 .00
Patients transfused (n) 2 (10%) 28 (41%) .02
PRBC (mL) 50 ± 116.8 308.8 ± 466.4 .00
FFP (units) 0.3 ± 0.8 1.23 ± 1.5 .00
PLT (units) 0 0.98 ± 1.1 .00
MV (h) 11.5 ± 4.6 15.1 ± 8.3* .01
ICU stay (h) 27.4 ± 12.8 55.1 ± 34.4 .00
Hospital stay (d) 6.4 ± 2.5 13.9 ± 3.7 .00
Values are expressed as means ± SD where shown. PT, Prothrombin time;
APTT, activated partial thromboplastin time; CTO, chest tube output;
PRBC, packed red blood cells; FFP, fresh-frozen plasma; PLT, platelets;
MV, mechanical ventilation.
*Data do not include 2 patients who had tracheostomies for respiratory
failure (mechanical ventilation ≥2 weeks).
TABLE 3. Incidence of complications
Tirofiban group Control group
(n = 20) (n = 68)
Type of complication 0* 20 (29%)* P value
Low cardiac output 0 4 (5.8%) .61
Atrial fibrillation 0 8 (11.7%) .24
AMI 0 2 (2.9%) .93
Bleeding reentry 0 2 (2.9%) .93
Sternal dehiscence 0 2 (2.9%) .93
Renal failure 0 2 (2.9%) .93
PNX 0 3 (4.4%) .79
MV prolonged (tracheostomy) 0 2 (2.9%) .93
Stroke 0 1 (1.4%) .98
Cognitive changes 0 3 (4.4%) .79
Death 0 0 —
AMI, Acute myocardial infarction; PNX, pneumothorax; MV, mechanical
ventilation.
*Number of patients with complications. Some of the 20 patients in the
control group had more than 1 complication.
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on adjacent platelets by adhesive plasma proteins, above all
fibrinogen. Clinical trials of several glycoprotein IIb/IIIa
inhibitors (abciximab, eptifibatide, and tirofiban) have
demonstrated an unequivocal clinical benefit of this potent
antithrombotic therapy in patients with acute coronary syn-
drome (irrespective of presence of percutaneous translumi-
nal coronary angioplasty), and in the future, an increasing
number of patients are likely to undergo treatment with
these molecules.12,13
Nevertheless, a significant number of patients may still
require urgent or emergency coronary artery bypass grafting
after this treatment: the main concern for the immediate
treatment of these patients is the potential for increased risk
of bleeding caused by the potent antiplatelet effect of these
agents. Since their approval for clinical use, more data exist
regarding the abciximab molecule (Reopro). Preoperative
treatment with abciximab does not increase surgical mortal-
ity, but exposure before an operation has been reported to
increase postoperative bleeding and transfusion require-
ments and is associated with a higher incidence of mediasti-
nal reentry.14 In our study the infusion of tirofiban
hydrochloride immediately before surgical intervention did
not adversely affect clinical outcome and did not have any
deleterious effect on postoperative bleeding, maintaining
hemoglobin and platelet counts at stable levels. Our ongoing
study shows that patients may safely undergo an operation
without increased incidence of transfusion or reexploration
rates when exposed preoperatively to tirofiban.
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